Abstract
While there is an emerging consensus that engagement of the Mu opioid receptor by opioids may modulate various stages the HIV life cycle (e.g.: increasing cell susceptibility to infection, promoting viral transcription, and depressing immune responses to virally-infected cells), the overall effect on latency and viral reservoirs remains unclear. Importantly, the hypothesis that the increase in immune activation observed in chronic opioid users by direct or indirect mechanisms (i.e., microbial translocation) would lead to a larger HIV reservoir after ART-suppression has not been supported to date. The potential for a subsequent decrease in reservoirs after ART-suppression has been postulated and is supported by early reports of opioid users having lower latent HIV burden. Here, we review experimental data supporting the link between opioid use and HIV modulation, as well as the scientific premise for expecting differential changes in immune activation and HIV reservoir between different medications for opioid use disorder. A better understanding of potential changes in HIV reservoirs relative to the engagement of the Mu opioid receptor and ART-mediated immune reconstitution will help guide future cure-directed studies in persons living with HIV and opioid use disorder.
Similar content being viewed by others
Change history
24 October 2020
The original version of this article unfortunately contained mistakes.
References
Abdel-Mohsen M et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10
Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M (2002) Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. Aids 16:2145–2149
Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS (2017) Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther 45:319–331
Akbarali HI, Dewey WL (2019) Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link? Nat Rev Gastroenterol Hepatol 16:323–324
Al-Hashimi M, Scott SW, Thompson JP, Lambert DG (2013) Opioids and immune modulation: more questions than answers. Br J Anaesth 111:80–88
Allam O, Samarani S, Mehraj V, Jenabian MA, Tremblay C, Routy JP, Amre D, Ahmad A (2018) HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation. PLoS One 13:e0194185
Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, Safren SA (2009) The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDs 23:455–462
Bachmann N et al (2019) Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun 10:3193
Bandera A, De Benedetto I, Bozzi G, Gori A (2018) Altered gut microbiome composition in HIV infection: causes, effects and potential intervention. Curr Opin HIV AIDS 13:73–80
Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher MR (2011) Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neuro-Oncol 17:291–302
Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, Dauer P, Chen C, Dalluge J, Johnson T, Roy S (2016) Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol 9:1418–1428
Bastard JP, Soulie C, Fellahi S, Haim-Boukobza S, Simon A, Katlama C, Calvez V, Marcelin AG, Capeau J (2012) Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 17:915–919
Bell JE, Brettle RP, Chiswick A, Simmonds P (1998) HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 121(Pt 11):2043–2052
Bilecki W, Wawrzczak-Bargiela A, Przewlocki R (2004) Activation of AP-1 and CRE-dependent gene expression via mu-opioid receptor. J Neurochem 90:874–882
Borner C, Kraus J (2013) Inhibition of NF-kappaB by opioids in T cells. J Immunol 191:4640–4647
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12:1365–1371
Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD (2012) Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics 11:605–618
Bryant HU, Bernton EW, Holaday JW (1988) Morphine pellet-induced immunomodulation in mice: temporal relationships. J Pharmacol Exp Ther 245:913–920
Burdo TH, Katner SN, Taffe MA, Fox HS (2006) Neuroimmunity, drugs of abuse, and neuroAIDS. J NeuroImmune Pharmacol 1:41–49
Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, Rosenberg ES, Williams KC, Grinspoon S (2011a) Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 204:1227–1236
Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC (2011b) Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 204:154–163
Byrd D, Murray J, Safdieh G, Morgello S (2012) Impact of opiate addiction on neuroinflammation in HIV. J Neuro-Oncol 18:364–373
Camilleri M, Lembo A, Katzka DA (2017) Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin Gastroenterol Hepatol 15:1338–1349
Canan C, Alexander GC, Moore R, Murimi I, Chander G, Lau B (2019) Medicaid trends in prescription opioid and non-opioid use by HIV status. Drug Alcohol Depend 197:141–148
Carrico AW, Cherenack EM, Roach ME, Riley ED, Oni O, Dilworth SE, Shoptaw S, Hunt P, Roy S, Pallikkuth S, Pahwa S (2018) Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS 32:767–771
Cary DC, Fujinaga K, Peterlin BM (2016) Molecular mechanisms of HIV latency. J Clin Invest 126:448–454
Chandra LC, Kumar V, Torben W, Vande Stouwe C, Winsauer P, Amedee A, Molina PE, Mohan M (2015) Chronic administration of Delta9-tetrahydrocannabinol induces intestinal anti-inflammatory microRNA expression during acute simian immunodeficiency virus infection of rhesus macaques. J Virol 89:1168–1181
Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ (2002) Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 168:4796–4801
Cheido MA, Gevorgyan MM, Zhukova EN (2014) Comparative evaluation of opioid-induced changes in immune reactivity of CBA mice. Bull Exp Biol Med 156:363–365
Cheung SC, Chattopadhyay SK, Morse HC 3rd, Pitha PM (1991) Expression of defective virus and cytokine genes in murine AIDS. J Virol 65:823–828
Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–188
Cornwell WD, Lewis MG, Fan X, Rappaport J, Rogers TJ (2013) Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques. J Neuroimmunol 265:43–50
Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM (2015) Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis 212:1361–1365
Dave RS, Khalili K (2010) Morphine treatment of human monocyte-derived macrophages induces differential miRNA and protein expression: impact on inflammation and oxidative stress in the central nervous system. J Cell Biochem 110:834–845
Dillon SM, Kibbie J, Lee EJ, Guo K, Santiago ML, Austin GL, Gianella S, Landay AL, Donovan AM, Frank DN, Mc CM, Wilson CC (2017) Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS 31:511–521
Donnadieu-Rigole H, Pansu N, Mura T, Pelletier S, Alarcon R, Gamon L, Perney P, Apparailly F, Lavigne JP, Dunyach-Remy C (2018) Beneficial effect of alcohol withdrawal on gut permeability and microbial translocation in patients with alcohol use disorder. Alcohol Clin Exp Res 42:32–40
Edelman EJ, Gordon KS, Tate JP, Becker WC, Bryant K, Crothers K, Gaither JR, Gibert CL, Gordon AJ, Marshall B, Rodriguez-Barradas MC, Samet JH, Skanderson M, Justice AC, Fiellin DA (2016) The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy. HIV Med 17:728–739
Edelman EJ, Gordon KS, Crothers K, Akgun K, Bryant KJ, Becker WC, Gaither JR, Gibert CL, Gordon AJ, Marshall BDL, Rodriguez-Barradas MC, Samet JH, Justice AC, Tate JP, Fiellin DA (2019) Association of Prescribed Opioids with Increased Risk of community-acquired pneumonia among patients with and without HIV. JAMA Intern Med 179:297–304
Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M (2007) Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 196:1779–1783
El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF (2005) Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 tat. Glia 50:91–106
El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF (2008a) CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 tat-exposed mice. J NeuroImmune Pharmacol 3:275–285
El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, Hauser KF (2008b) Morphine exacerbates HIV-1 tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-kappaB trafficking and transcription. PLoS One 3:e4093
Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A (2015) The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res 37:223–236
Fernandez S, Price P, McKinnon EJ, Nolan RC, French MA (2006) Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 120:163–170
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512–517
Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG, Richardson MW, Amini S, Morgello S, Khalili K, Rappaport J (2001) CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neuro-Oncol 7:528–541
French MA, King MS, Tschampa JM, da Silva BA, Landay AL (2009) Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis 200:1212–1215
Galligan JJ (2015) HIV, opiates, and enteric neuron dysfunction. Neurogastroenterol Motil 27:449–454
Garcia JB, Cardoso MG, Dos-Santos MC (2012) Opioids and the immune system: clinical relevance. Rev Bras Anestesiol 62:709–718
Gessi S, Borea PA, Bencivenni S, Fazzi D, Varani K, Merighi S (2016) The activation of mu-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia. FEBS Lett 590:2813–2826
Gill AJ, Kolson DL (2014) Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep 11:325–335
Giugliano D, Ceriello A, Quatraro A, D'Onofrio F (1985) Endogenous opiates, heroin addiction, and non-insulin-dependent diabetes. Lancet 2:769–770
Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R (2006) Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 194:29–37
Guo CJ, Li Y, Tian S, Wang X, Douglas SD, Ho WZ (2002) Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 50:435–442
Happel C, Kutzler M, Rogers TJ (2011) Opioid-induced chemokine expression requires NF-kappaB activity: the role of PKCzeta. J Leukoc Biol 89:301–309
Hauser KF, El-Hage N, Buch S, Berger JR, Tyor WR, Nath A, Bruce-Keller AJ, Knapp PE (2005) Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res 8:63–80
Hauser KF, Fitting S, Dever SM, Podhaizer EM, Knapp PE (2012) Opiate drug use and the pathophysiology of neuroAIDS. Curr HIV Res 10:435–452
Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, Landay AL, Jaworowski A, Crowe SM (2012) HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. Aids 26:843–853
Henderson LJ, Reoma LB, Kovacs JA, Nath A (2020) Advances toward curing HIV-1 infection in tissue reservoirs. J Virol 94
Hileman OCBE, Gabriel J, Kettelhut A, Kosco JC, Labbato D, Rodgers TO, Smith CA, Funderburg N, McComsey GA (2020) Impact of intravenous heroin and HIV on gut integrity and immune activation. In: Conference on Retroviruses and Opportunistic Infecitons. Boston
Holzer P (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361:192–195
Holzer P (2008) New approaches to the treatment of opioid-induced constipation. Eur Rev Med Pharmacol Sci 12(Suppl 1):119–127
Hunt PW (2012) HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 9:139–147
Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187:1534–1543
Jaureguiberry-Bravo M, Lopez L, Berman JW (2018) Frontline science: buprenorphine decreases CCL2-mediated migration of CD14(+) CD16(+) monocytes. J Leukoc Biol 104:1049–1059
Karagiannis TT, Cleary JP Jr, Gok B, Henderson AJ, Martin NG, Yajima M, Nelson EC, Cheng CS (2020) Single cell transcriptomics reveals opioid usage evokes widespread suppression of antiviral gene program. Nat Commun 11:2611
Khansari M, Sohrabi M, Zamani F (2013) The Useage of opioids and their adverse effects in gastrointestinal practice: A review. Middle East J Dig Dis 5:5–16
Khoury G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, Van Lint C (2018) The molecular biology of HIV latency. Adv Exp Med Biol 1075:187–212
Kirk GD, Mehta SH, Astemborski J, Ritter JD, Laird G, Siliciano R (2020) Nonstructured treatment interruptions contribute to latent HIV-1 reservoir in PWID. In: Conference on Retroviruses and Opportunistic Infections. Boston
Koay WLA, Siems LV, Persaud D (2018) The microbiome and HIV persistence: implications for viral remission and cure. Curr Opin HIV AIDS 13:61–68
Kumar R, Torres C, Yamamura Y, Rodriguez I, Martinez M, Staprans S, Donahoe RM, Kraiselburd E, Stephens EB, Kumar A (2004) Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J Virol 78:11425–11428
Le Bastard Q, Al-Ghalith GA, Gregoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E (2018) Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 47:332–345
Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, Gripshover B, Salata RA, Taege A, Lisgaris M, McComsey GA, Kirchner E, Baum J, Shive C, Asaad R, Kalayjian RC, Sieg SF, Rodriguez B (2011) Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 204:1217–1226
Lee GQ, Orlova-Fink N, Einkauf K, Chowdhury FZ, Sun X, Harrington S, Kuo HH, Hua S, Chen HR, Ouyang Z, Reddy K, Dong K, Ndung'u T, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M (2017) Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest 127:2689–2696
Leibrand CR, Paris JJ, Jones AM, Masuda QN, Halquist MS, Kim WK, Knapp PE, Kashuba ADM, Hauser KF, McRae M (2019) HIV-1 tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. J Neuro-Oncol 25:560–577
Li Y, Merrill JD, Mooney K, Song L, Wang X, Guo CJ, Savani RC, Metzger DS, Douglas SD, Ho WZ (2003) Morphine enhances HIV infection of neonatal macrophages. Pediatr Res 54:282–288
Lujan JA, Rugeles MT, Taborda NA (2019) Contribution of the microbiota to intestinal homeostasis and its role in the pathogenesis of HIV-1 infection. Curr HIV Res 17:13–25
Martin JL, Koodie L, Krishnan AG, Charboneau R, Barke RA, Roy S (2010) Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol 176:786–799
Martin-Kleiner I, Balog T, Gabrilovac J (2006) Signal transduction induced by opioids in immune cells: a review. Neuroimmunomodulation 13:1–7
Mbonye U, Karn J (2017) The molecular basis for human immunodeficiency virus latency. Annu Rev Virol 4:261–285
McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699–714
McLane VD, Cao L, Willis CL (2014) Morphine increases hippocampal viral load and suppresses frontal lobe CCL5 expression in the LP-BM5 AIDS model. J Neuroimmunol 269:44–51
McNeil AJ (1997) Bayes estimates for immunological progression rates in HIV disease. Stat Med 16:2555–2572
Mehandru S, Deren S, Kang SY, Banfield A, Garg A, Garmon D, LaMar M, Evering TH, Markowitz M (2015) Behavioural, mucosal and systemic immune parameters in HIV-infected and uninfected injection drug users. J Addict Res Ther 6:1–8
Meijerink H, Wisaksana R, Iskandar S, den Heijer M, van der Ven AJ, Alisjahbana B, van Crevel R (2014) Injecting drug use is associated with a more rapid CD4 cell decline among treatment naive HIV-positive patients in Indonesia. J Int AIDS Soc 17:18844
Meng J, Yu H, Ma J, Wang J, Banerjee S, Charboneau R, Barke RA, Roy S (2013) Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One 8:e54040
Meng J, Sindberg GM, Roy S (2015) Disruption of gut homeostasis by opioids accelerates HIV disease progression. Front Microbiol 6:643
Meng J, Banerjee S, Zhang L, Sindberg G, Moidunny S, Li B, Robbins DJ, Girotra M, Segura B, Ramakrishnan S, Roy S (2019) Opioids impair intestinal epithelial repair in HIV-infected humanized mice. Front Immunol 10:2999
Meyer VJ, Rubin LH, Martin E, Weber KM, Cohen MH, Golub ET, Valcour V, Young MA, Crystal H, Anastos K, Aouizerat BE, Milam J, Maki PM (2013) HIV and recent illicit drug use interact to affect verbal memory in women. J Acquir Immune Defic Syndr 63:67–76
Monnig MA, Kahler CW, Cioe PA, Tucker L, Monti PM, Mayer KH, Ramratnam B (2016) Alcohol use predicts elevation in inflammatory marker soluble CD14 in men living with HIV. AIDS Care 28:1434–1440
Moroz E, Albrecht RA, Aden B, Beeder AB, Yuan J, Garcia-Sastre A, Edlin BR, Salvatore M (2016) Active opioid use does not attenuate the humoral responses to inactivated influenza vaccine. Vaccine 34:1363–1369
Muller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, Emmanuel A, Laroche F, Meissner W, Morlion B (2017) Opioid-induced constipation and bowel dysfunction: A clinical guideline. Pain Med 18:1837–1863
Mysels DJ, Sullivan MA (2010) The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag 6:445–452
Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H (2011) High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 11:43
Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201:1788–1795
Ninkovic J, Roy S (2013) Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids 45:9–24
Novati S, Sacchi P, Cima S, Zuccaro V, Columpsi P, Pagani L, Filice G, Bruno R (2015) General issues on microbial translocation in HIV-infected patients. Eur Rev Med Pharmacol Sci 19:866–878
Palmer CS, Ostrowski M, Gouillou M, Tsai L, Yu D, Zhou J, Henstridge DC, Maisa A, Hearps AC, Lewin SR, Landay A, Jaworowski A, McCune JM, Crowe SM (2014) Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS 28:297–309
Patro SC, Azzoni L, Joseph J, Fair MG, Sierra-Madero JG, Rassool MS, Sanne I, Montaner LJ (2016) Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol 100:223–231
Peng J, Sarkar S, Chang SL (2012) Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend 124:223–228
Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF (1987) Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol 138:3907–3912
Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, Diana M (2006) Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 83:163–168
Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581–590
Prevention CfDCa (2020) HIV surveillance report, 2018 (updated). In: HIV Surveillance Report
Purohit V, Rapaka RS, Rutter J, Shurtleff D (2012) Do opioids activate latent HIV-1 by down-regulating anti-HIV microRNAs? J NeuroImmune Pharmacol 7:519–523
Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H (2007) Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 7:5
Rapeli P, Fabritius C, Kalska H, Alho H (2011) Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol 11:13
Reardon S (2019) The US opioid epidemic is driving a spike in infectious diseases. Nature 571:15–16
Reddy PV, Pilakka-Kanthikeel S, Saxena SK, Saiyed Z, Nair MP (2012) Interactive effects of morphine on HIV infection: role in HIV-associated neurocognitive disorder. AIDS Res Treat 2012:953678
Reynolds JL, Law WC, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Mammen MJ, Yong KT, Hui R, Prasad PN, Schwartz SA (2012) Morphine and galectin-1 modulate HIV-1 infection of human monocyte-derived macrophages. J Immunol 188:3757–3765
Rizzo MD, Henriquez JE, Blevins LK, Bach A, Crawford RB, Kaminski NE (2020) Targeting cannabinoid receptor 2 on peripheral leukocytes to attenuate inflammatory mechanisms implicated in HIV-associated neurocognitive disorder. J NeuroImmune Pharmacol
Rogers DF, Barnes PJ (1989) Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet 1:930–932
Ronan MV, Herzig SJ (2016) Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood) 35:832–837
Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, Kirchner VA, Koodie L, Ma J, Meng J, Barke RA (2011) Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J NeuroImmune Pharmacol 6:442–465
Sacerdote P, Franchi S, Panerai AE (2012) Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression. Curr Pharm Des 18:6034–6042
Sachdeva N, Asthana V, Brewer TH, Garcia D, Asthana D (2008) Impaired restoration of plasmacytoid dendritic cells in HIV-1-infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines. J Immunol 181:2887–2897
Saurer TB, Carrigan KA, Ijames SG, Lysle DT (2004) Morphine-induced alterations of immune status are blocked by the dopamine D2-like receptor agonist 7-OH-DPAT. J Neuroimmunol 148:54–62
Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL (2019) Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: A study of statewide discharge data. Ann Intern Med 170:31–40
Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H (2005) Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 25:490–493
Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Kufner H, Kagerer S, Haberthur A (2011) A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study. Am J Drug Alcohol Abuse 37:497–508
Steele AD, Henderson EE, Rogers TJ (2003) Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309:99–107
Stimson GV, Cook C, Bridge J, Rio-Navarro J, Lines R, Barrett D (2010) Three cents a day is not enough: resourcing HIV-related harm reduction on a global basis. In
Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR (2011) Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 1399:96–115
Strazza M, Pirrone V, Wigdahl B, Dampier W, Lin W, Feng R, Maubert ME, Weksler B, Romero IA, Couraud PO, Nonnemacher MR (2016) Prolonged morphine exposure induces increased firm adhesion in an in vitro model of the blood-brain barrier. Int J Mol Sci 17
Underwood ML, Nguyen T, Uebelhoer LS, Kunkel LE, Korthuis PT, Lancioni CL (2020) Altered monocyte phenotype and dysregulated innate cytokine responses among people living with HIV and opioid-use disorder. AIDS 34:177–188
Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A, Team ACTGP (2002) Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. Aids 16:1859–1866
Vallecillo G, Robles MJ, Torrens M, Samos P, Roquer A, Martires PK, Sanvisens A, Muga R, Pedro-Botet J (2018) Metabolic syndrome among individuals with heroin use disorders on methadone therapy: prevalence, characteristics, and related factors. Subst Abus 39:46–51
Visconti AJ, Sell J, Greenblatt AD (2019) Primary Care for Persons who Inject Drugs. Am Fam Physician 99:109–116
Volkow ND, Montaner J (2011) The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood) 30:1411–1419
Volpe GE, Ward H, Mwamburi M, Dinh D, Bhalchandra S, Wanke C, Kane AV (2014) Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation. J Stud Alcohol Drugs 75:347–357
Wang F, Roy S (2017) Gut homeostasis, microbial Dysbiosis, and opioids. Toxicol Pathol 45:150–156
Wang J, Barke RA, Charboneau R, Loh HH, Roy S (2003) Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 278:37622–37631
Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ, Ho WZ (2011) Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol 178:41–47
Wang Y, Wang X, Ye L, Li J, Song L, Fulambarkar N, Ho W (2012) Morphine suppresses IFN signaling pathway and enhances AIDS virus infection. PLoS One 7:e31167
Wang X, Ma TC, Li JL, Zhou Y, Geller EB, Adler MW, Peng JS, Zhou W, Zhou DJ, Ho WZ (2015) Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol 6:1230
Wang MR, Wu DD, Luo F, Zhong CJ, Wang X, Zhu N, Wu YJ, Hu HT, Feng Y, Wang X, Xiong HR, Hou W (2020) Methadone inhibits viral restriction factors and facilitates HIV infection in macrophages. Front Immunol 11:1253
Weiner LD, Retuerto M, Hager CL, El Kamari V, Shan L, Sattar A, Kulkarni M, Funderburg N, Ghannoum MA, Dirajlal-Fargo S, McComsey GA (2019) Fungal translocation is associated with immune activation and systemic inflammation in treated HIV. AIDS Res Hum Retrovir 35:461–472
Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF, Grijalva CG (2019) Long-acting opioid use and the risk of serious infections: A retrospective cohort study. Clin Infect Dis 68:1862–1869
Yousif S, Saubamea B, Cisternino S, Marie-Claire C, Dauchy S, Scherrmann JM, Decleves X (2008) Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein. J Neurochem 107:647–657
Yuan CS, Foss JF, O'Connor M, Roizen MF, Moss J (1998) Effects of low-dose morphine on gastric emptying in healthy volunteers. J Clin Pharmacol 38:1017–1020
Zaki NG, Osman A, Moustafa H, Saad AH (2006) Alterations of immune functions in heroin addicts. Egypt J Immunol 13:153–171
Zevin AS, McKinnon L, Burgener A, Klatt NR (2016) Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS 11:182–190
Zhang EY, Xiong J, Parker BL, Chen AY, Fields PE, Ma X, Qiu J, Yankee TM (2011) Depletion and recovery of lymphoid subsets following morphine administration. Br J Pharmacol 164:1829–1844
Zheng YH, Jeang KT, Tokunaga K (2012) Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology 9:112
Zhu JW, Liu FL, Mu D, Deng DY, Zheng YT (2016) Increased expression and dysregulated association of restriction factors and type I interferon in HIV, HCV mono- and co-infected patients. J Med Virol 88:987–995
Zhu JW, Liu FL, Mu D, Deng DY, Zheng YT (2017) Heroin use is associated with lower levels of restriction factors and type I interferon expression and facilitates HIV-1 replication. Microbes Infect 19:288–294
Funding
Funding for this work was provided by grants to LJM (NIH: 1UM1Al126620, R01 DA048728, R01 DA049666), Robert I. Jacobs Fund of the Philadelphia Foundation, the Kean Family Professorship, and the Wistar Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Authors have no conflict of Interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Azzoni, L., Metzger, D. & Montaner, L.J. Effect of Opioid Use on Immune Activation and HIV Persistence on ART. J Neuroimmune Pharmacol 15, 643–657 (2020). https://doi.org/10.1007/s11481-020-09959-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-020-09959-y